Impacts for the Company
The stability studies enable the business to support more patients across the UK to access urgent medications as efficiently as possible. Improving product stability enables products to be prepared in a more timely manner and ensures that products are available as soon as required to treat critical illness. Not only can the company improve patient access but can also reach a wider patient group by having more readily available compounded medicines.
Impacts for the Academic Team
Although the project does not affect the academic team and there will be no lasting legacy such as published papers (due to Intellectual property restrictions from the company), with the Associate working in the Cancer Research UK (CRUK) labs she has been able to pass on her knowledge from previously working in an industry laboratory.
This was important as the university had not previously had a Capillary Zone Electrophoresis (CZE) system, the Associate had used this system in her previous workplace and was able to help troubleshoot all the issues she had experienced.
Impacts for the KTP Associate
Through the KTP, Yvonne significantly expanded her technical expertise by developing knowledge and experience in assay methodologies.
The Associate development budget provided access to specialist training opportunities that would otherwise have been difficult to undertake due to time and cost constraints. This included project management training, enhancing Yvonne’s ability to manage complex projects within the pharmaceutical sector.
Regular engagement with the KTP team at quarterly meetings, helped Yvonne build confidence in communicating technical information and strengthened her professional and leadership skills.